Table 2 Pharmacotherapy after the PT-X intervention period

Anticoagulants

35 (92%)

Platelet inhibitors

2 (5%)

Heart rate regulators ^a

32 (84%)

Calcium channel antagonists ^b

4 (11%)

ACE-I/ARB

24 (63%)

Alpha-receptor antagonists

–

Diuretics

9 (24%)

Nitrates

3 (8%)

Potassium supplement

2 (5%)

Oral antidiabetics

2 (5%)

Lipid modulators

17 (45%)

Thyroid hormone

3 (8%)

COPD medication

3 (8%)